Table 2.
miRNA | Training stage | Testing stage | External validation stage | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
NPC | NC | FC | P‐value | NPC | NC | FC | P‐value | NPC | NC | FC | P‐value | |
let‐7b‐5p | 3.17 ± 0.69 | 4.30 ± 0.82 | 2.19 | <.001 | 2.86 ± 1.51 | 4.70 ± 1.37 | 3.59 | <.001 | 3.70 ± 0.93 | 5.16 ± 0.70 | 2.76 | <.001 |
miR‐140‐3p | 6.00 ± 1.16 | 6.63 ± 1.46 | 1.54 | .034 | 4.72 ± 2.14 | 6.54 ± 1.81 | 3.54 | <.001 | 7.58 ± 0.72 | 8.35 ± 0.80 | 1.71 | <.001 |
miR‐144‐3p | 6.04 ± 1.27 | 6.67 ± 1.15 | 1.55 | .020 | 3.81 ± 1.72 | 5.15 ± 2.11 | 2.53 | <.001 | 5.53 ± 1.67 | 6.31 ± 1.67 | 1.72 | .001 |
miR‐17‐5p | 2.28 ± 0.79 | 4.10 ± 0.99 | 3.54 | <.001 | 0.98 ± 1.76 | 3.55 ± 1.15 | 5.92 | <.001 | 4.34 ± 1.05 | 5.76 ± 1.03 | 2.66 | <.001 |
miR‐20b‐5p | 5.55 ± 0.75 | 7.05 ± 0.93 | 2.84 | <.001 | 4.31 ± 1.85 | 6.65 ± 1.33 | 5.06 | <.001 | 6.51 ± 0.95 | 7.88 ± 0.88 | 2.57 | <.001 |
miR‐205‐5p | 9.27 ± 1.26 | 10.09 ± 1.09 | 1.77 | .014 | 7.94 ± 1.96 | 9.28 ± 2.00 | 2.53 | <.001 | 9.02 ± 2.00 | 9.87 ± 1.40 | 1.80 | .047 |
miR‐20a‐5p | 4.34 ± 1.08 | 6.38 ± 1.09 | 4.12 | <.001 | 5.86 ± 2.60 | 7.70 ± 1.87 | 3.56 | <.001 | 5.14 ± 0.66 | 5.93 ± 0.61 | 1.74 | .028 |
Abbreviations: FC, fold change; NCs, normal controls; NPC, nasopharyngeal carcinoma.